Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
METHYLPHENIDATE HYDROCHLORIDE (UNII: 4B3SC438HI) (METHYLPHENIDATE - UNII:207ZZ9QZ49)
Trigen Laboratories, LLC
METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE 54 mg
ORAL
PRESCRIPTION DRUG
Methylphenidate hydrochloride extended-release tablets USP is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see Clinical Studies (14)] . A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; lo
Methylphenidate hydrochloride extended-release tablets are available in 18, 27, 36, 54, and 72 mg strengths. The 18 mg tablets are yellow with “TL706” imprinted in black ink, 27 mg tablets are gray with “TL707” imprinted in black ink, 36 mg tablets are white with “TL708” imprinted in black ink, 54 mg tablets are pink with “TL709" imprinted in black ink, and 72 mg tablets are blue with “TL710” imprinted in black ink. The tablets are supplied: Storage and Handling Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from humidity.
Abbreviated New Drug Application
Trigen Laboratories, LLC ---------- MedGuide MEDICATION GUIDE Methylphenidate hydrochloride extended-release tablets USP CII (METH-il-FEN-i-date) Read the Medication Guide that comes with methylphenidate hydrochloride extended-release tablets USP before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your or your child's treatment with methylphenidate hydrochloride extended-release tablets USP. What is the most important information I should know about methylphenidate hydrochloride extended- release tablets? The following have been reported with use of methylphenidate HCl and other stimulant medicines: 1. Heart-related problems: · sudden death in patients who have heart problems or heart defects · stroke and heart attack in adults · increased blood pressure and heart rate Tell your doctor if you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. Your doctor should check you or your child carefully for heart problems before starting methylphenidate hydrochloride extended-release tablets. Your doctor should check your or your child's blood pressure and heart rate regularly during treatment with methylphenidate hydrochloride extended-release tablets. Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking methylphenidate hydrochloride extended-release tablets. 2. Mental (Psychiatric) problems: All Patients · new or worse behavior and thought problems · new or worse bipolar illness · new or worse aggressive behavior or hostility Children and Teenagers · new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. Call your doctor right away Citiți documentul complet
METHYLPHENIDATE HYDROCHLORIDE- METHYLPHENIDATE HYDROCHLORIDE TABLET, EXTENDED RELEASE TRIGEN LABORATORIES, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS USP. METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS USP, FOR ORAL USE CII INITIAL U.S. APPROVAL: 2000 WARNING: DRUG DEPENDENCE _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS SHOULD BE GIVEN CAUTIOUSLY TO PATIENTS WITH A HISTORY OF DRUG DEPENDENCE OR ALCOHOLISM. CHRONIC ABUSIVE USE CAN LEAD TO MARKED TOLERANCE AND PSYCHOLOGICAL DEPENDENCE, WITH VARYING DEGREES OF ABNORMAL BEHAVIOR. INDICATIONS AND USAGE Methylphenidate hydrochloride extended-release tablets USP is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65. (1) DOSAGE AND ADMINISTRATION Methylphenidate hydrochloride extended-release tablets should be taken once daily in the morning and swallowed whole with the aid of liquids. Methylphenidate hydrochloride extended-release tablets should not be chewed or crushed. Methylphenidate hydrochloride extended-release tablets may be taken with or without food. (2.1) For children and adolescents new to methylphenidate, the recommended starting dosage is 18 mg once daily. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 54 mg/day in children and 72 mg/day in adolescents. (2.2) For adult patients new to methylphenidate, the recommended starting dose is 18 or 36 mg/day. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 72 mg/day for adults. (2.2) For patients currently using methylphenidate, dosing is based on current dose regimen and clinical judgment. (2.3) DOSAGE F Citiți documentul complet